Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CONMED (CNMD)

CONMED to replace CFO Todd Garner; he stays through November 2, 2026 as consultant

Neutral Impact 4 of 5 leadership Written later

CONMED announced that Chief Financial Officer Todd Garner is separating from the company, effective on the earlier of March 15, 2026 or the appointment of a new permanent CFO. The company has retained an executive search firm to find his successor, and the filing states the separation did not arise from any disagreement about operations, policies, financial results or accounting practices.

Key points

  • CFO Todd Garner's separation takes effect on the earlier of March 15, 2026 or the appointment of a new permanent CFO
  • Garner remains employed through November 2, 2026 under a Transition Letter Agreement dated January 6, 2026
  • During the consulting period he keeps his base salary and is eligible for a pro-rated 2026 bonus, but gets no annual equity award grant in Q1 2026
  • The company has retained an executive search firm to find a new CFO

The filing

CompanyCONMED (CNMD)
Form8-K, current report
Filed with the SECJan 8, 2026, 5:00 PM ET
Accession number0001174947-26-000017

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.